SecBot SecBot
PRESS-RELEASE ·Filed May 13, 2026

PDSB

PDS Biotechnology Corporation
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat and cost reduction are positive, but the stock's movement will hinge on clinical catalysts, specifically the amended VERSATILE-003 protocol and any FDA feedback on accelerated approval. Monitor the 8:00 am ET investor webcast for updates on trial enrollment restart and regulatory interactions. The $21.7M cash position provides runway into mid-2027 at current burn rate, but dilution risk remains high given the pre-revenue stage.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.33
T+0 close · May 13, 2026 · via day close
Latest settled
−41.71%
T+60 · $0.7753
Vs SPY
−46.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $1.33entry
  2. T+1 · 6mo ago +7.52%α +6.74% · $1.43
  3. T+5 · 6mo ago −24.81%α −23.65% · $1.00
  4. T+20 · 5mo ago −15.79%α −15.18% · $1.12
  5. T+60 · 3mo ago −41.71%α −46.14% · $0.7753
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, driven by lower R&D and G&A expenses. The EPS of -$0.13 beat the consensus estimate of -$0.14 by 7.1%, but the company remains a pre-revenue clinical-stage biotech with no approved products and a cash runway of $21.7M. The key catalyst is the amended VERSATILE-003 Phase 3 trial protocol incorporating PFS as an interim endpoint, which could enable an accelerated approval pathway for PDS0101 in head and neck cancer.

Key Financial Metrics

EPS
−$0.13
est −$0.14 · +7.1%
Rating
beat

Key Facts

  • Q1 2026 net loss of $7.3M ($0.13/share) vs $8.5M ($0.21/share) in Q1 2025
  • EPS of -$0.13 beat consensus estimate of -$0.14 by 7.1%
  • Cash balance of $21.7M as of March 31, 2026, down from $26.7M at year-end 2025
  • Amended VERSATILE-003 Phase 3 trial to include PFS as interim primary endpoint, potentially enabling accelerated approval for PDS0101
  • Positive mCRC data published in JCO: 77.8% ORR at 6 months and ~85% 24-month survival rate with PDS01ADC combination
  • R&D expenses decreased to $3.5M from $5.8M YoY due to lower clinical and manufacturing costs
  • Accumulated deficit of $224M; total stockholders' equity of $3.9M

Financial Impact

Q1 2026 net loss improved by $1.2M YoY; cash burn of ~$5M in the quarter; no revenue generated

net losscashR&D expensesoperating expenses

Risk Factors

  • Pre-revenue biotech with no approved products; entirely dependent on clinical trial success
  • Cash burn of ~$5M/quarter; $21.7M cash provides limited runway without additional financing
  • VERSATILE-003 trial amendment may face FDA pushback on accelerated approval pathway
  • High dilution risk: weighted average shares outstanding increased 37% YoY to 55.5M
  • Accumulated deficit of $224M with no near-term revenue prospects

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293836

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026